Compare MRKR & MLSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | MLSS |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 22.1M |
| IPO Year | 2010 | 1996 |
| Metric | MRKR | MLSS |
|---|---|---|
| Price | $1.21 | $0.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $1.00 |
| AVG Volume (30 Days) | 62.4K | ★ 122.0K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,973,982.00 |
| Revenue This Year | N/A | $12.64 |
| Revenue Next Year | $936.27 | $8.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.99 |
| 52 Week Low | $0.81 | $0.22 |
| 52 Week High | $2.46 | $0.68 |
| Indicator | MRKR | MLSS |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 54.37 |
| Support Level | $1.17 | $0.24 |
| Resistance Level | $1.52 | $0.44 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 1.76 | 56.95 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.